Tremblay, Gabriel http://orcid.org/0000-0003-0623-3545
Daniele, Patrick
Breeze, Janis
Li, Lingling
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Engelhardt, Monika
Chari, Ajaj
Nooka, Ajay
Vogl, Dan
Gavriatopoulou, Maria
Dimopoulos, Meletios-Athanasios
Richardson, Paul
Biran, Noa
Siegel, David
Vlummens, Philip
Doyen, Chantal
Facon, Thierry
Mohty, Mohamad
Meuleman, Nathalie
Levy, Moshe
Costa, Luciano
Hoffman, James E.
Delforge, Michel
Kaminetzky, David
Weisel, Katja
Raab, Marc
Dingli, David
Tuchman, Sascha
Laurent, Frenzel
Vij, Ravi
Schiller, Gary
Moreau, Philippe
Richter, Joshua
Schreder, Martin
Podar, Klaus
Parker, Terri
Cornell, Robert Frank
Lionel, Karlin
Choquet, Sylvain
Sundar, Jagannath
Funding for this research was provided by:
Karyopharm Therapeutics
Article History
Received: 13 November 2020
Accepted: 7 June 2021
First Online: 6 September 2021
Declarations
:
: This study was performed in compliance with the ethical principles that originate from the Declaration of Helsinki and are consistent with the International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and regulatory requirements as applicable. The study protocol was approved by the institutional review board or an independent ethics committee at each study center. Written informed consent in accordance with federal, local, and institutional guidelines was obtained from all patients. A list of Institutional Ethics Committees (IECs) and Institutional Review Boards (IRBs) is provided as a InternalRef removed.
: Not applicable.
: Gabriel Tremblay, Janis Breeze and Patrick Daniele are employees of Purple Squirrel Economics, which received funding from Karyopharm Therapeutics Inc. to conduct the analysis. Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman are employees of Karyopharm Therapeutics Inc. All other authors were investigators in the STORM trial.